The American subsidiary, named the TSO3 Corporation, is slated to open its doors in August, the Québec City-based company said.
“Alone and together with our sales and service partner Getinge Infection Control, the company has made great strides, which we believe will result in securing contract positions with the largest and leading group purchasing organizations and integrated delivery networks. In addition, TSO3 is ushering “scores” of quotes through their individual processes, many of which the company expects to successfully close. As a result of these efforts, it became clear that it was time to execute our plans to open a U.S. location focused on the education and ongoing service requirements of the U.S. customers. While the foundation and technical expertise of the company is and will remain in Quebec City, establishing a presence in the U.S., which represents 40% of the worldwide market, will allow us to more effectively reach out to and service this high opportunity market,” CEO Richard Rumble said in a prepared release.
TSO3 is the developer of the Sterizone VP4 Sterilizer, a dual sterilant, low-temperature single-cycle sterilization system that uses vaporized hydrogen peroxide and ozone, the company said.
The Sterizone VP4 was cleared for commercialization in the U.S. in December last year, TSO3 said.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.